This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (69)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Hypertension  • Alert me on articles by topic

A Comparison of Primary vs Secondary Prevention

Steven A. Grover, MD, MPA, FRCPC; Steve Paquet, MSc; Carey Levinton, BSc; Louis Coupal, MSc; Hanna Zowall, MA

Arch Intern Med. 1998;158:655-662.

Objectives  To compare the potential years of life saved (YOLS) associated with risk factor modification in the primary and secondary prevention of cardiovascular disease (CVD).

Methods  The CVD life expectancy model estimates the risk of death due to coronary disease, stroke, and other causes based on the levels of independent risk factors (such as age, blood pressure, and blood lipid levels) found in the cohort of the Lipid Research Clinics. The model was validated by comparing its predictions with the observed fatal outcomes of 9 randomized clinical trials. We then estimated the YOLS associated with treating hyperlipidemia or hypertension among hypothetical patient groups with and without CVD at baseline. We defined high-risk patients as those with 3 risk factors (hyperlipidemia, cigarette smoking, and hypertension) and low-risk patients as those with isolated hypertension or hyperlipidemia.

Results  The fatal events predicted by the model were consistent with the clinical trial results. Among men and women with hyperlipidemia without CVD, the forecasted benefits of lipid therapy were substantially greater among high-risk groups vs low-risk groups (4.74-0.78 YOLS vs 2.50-0.25 YOLS, respectively). Among those with CVD, the forecasted benefits of treatment were similar for both high-risk and low-risk groups (4.65-0.65 YOLS vs 3.84-0.58 YOLS, respectively). The results for hypertension therapy also demonstrated greater benefits for high-risk vs low-risk patients undergoing primary prevention therapy (1.34-0.29 YOLS vs 0.85-0.13 YOLS, respectively), and the forecasted benefits in secondary prevention were similar (1.26-0.23 YOLS vs 1.00-0.23 YOLS, respectively).

Conclusions  The clinical approach to risk factor modification in primary prevention should be different from that in secondary prevention. The forecasted benefits of therapy among patients without CVD are greatest in the presence of other risk factors. Among those with CVD, the benefits of therapy are equivalent, thereby obviating the need to target high-risk patients.

From the Centre for the Analysis of Cost-Effective Care (Dr Grover, Mr Paquet, Mr Levinton, Mr Coupal, and Ms Zowall) and the Divisions of General Internal Medicine (Dr Grover) and Clinical Epidemiology (Dr Grover, Mr Paquet, Mr Levinton, Mr Coupal, and Ms Zowall), Montreal General Hospital; the Departments of Medicine and Epidemiology and Biostatistics (Dr Grover), McGill University, Montreal, Quebec.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy: The CHECK-UP Study: A Randomized Controlled Trial
Grover et al.
Arch Intern Med 2007;167:2296-2303.
ABSTRACT | FULL TEXT  

Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes
Coleman et al.
Diabetes Care 2007;30:1292-1293.
FULL TEXT  

Life-years-gained from population risk factor changes and modern cardiology treatments in Ireland
Kabir et al.
Eur J Public Health 2007;17:193-198.
ABSTRACT | FULL TEXT  

The Prevalence of Erectile Dysfunction in the Primary Care Setting: Importance of Risk Factors for Diabetes and Vascular Disease
Grover et al.
Arch Intern Med 2006;166:213-219.
ABSTRACT | FULL TEXT  

Life-Years Gained From Modern Cardiological Treatments and Population Risk Factor Changes in England and Wales, 1981-2000
Unal et al.
Am. J. Public Health 2005;95:103-108.
ABSTRACT | FULL TEXT  

Treating Osteoarthritis With Cyclooxygenase-2-Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization?
Grover et al.
Hypertension 2005;45:92-97.
ABSTRACT | FULL TEXT  

The Relative Impact of Inadequate Primary and Secondary Prevention on Cardiovascular Mortality in the United States
Qureshi et al.
Stroke 2004;35:2346-2350.
ABSTRACT | FULL TEXT  

Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries
von Birgelen et al.
Circulation 2004;110:1579-1585.
ABSTRACT | FULL TEXT  

Blood Pressure Lowering and Life Expectancy Based on a Markov Model of Cardiovascular Events
Sesso et al.
Hypertension 2003;42:885-890.
ABSTRACT | FULL TEXT  

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy et al.
Eur Heart J 2003;24:987-1003.
ABSTRACT | FULL TEXT  

The Importance of Indirect Costs in Primary Cardiovascular Disease Prevention: Can We Save Lives and Money With Statins?
Grover et al.
Arch Intern Med 2003;163:333-339.
ABSTRACT | FULL TEXT  

Primary Prevention of Cardiovascular Disease: A Call to Action
Bonow
Circulation 2002;106:3140-3141.
FULL TEXT  

Ineffective Secondary Prevention in Survivors of Cardiovascular Events in the US Population: Report From the Third National Health and Nutrition Examination Survey
Qureshi et al.
Arch Intern Med 2001;161:1621-1628.
ABSTRACT | FULL TEXT  

Ten Years of Life: Is It a Matter of Choice?
Fraser and Shavlik
Arch Intern Med 2001;161:1645-1652.
ABSTRACT | FULL TEXT  

Evidence based management of hypertension: Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review
Padwal et al.
BMJ 2001;322:977-980.
FULL TEXT  

Cardiovascular Status of Carriers of the Apolipoprotein A-IMilano Mutant : The Limone sul Garda Study
Sirtori et al.
Circulation 2001;103:1949-1954.
ABSTRACT | FULL TEXT  

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?
Grover et al.
Diabetes Care 2001;24:45-50.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated?
Grover et al.
Circulation 2000;102:722-727.
ABSTRACT | FULL TEXT  

When should hypertension be treated? The different perspectives of Canadian family physicians and patients
McAlister et al.
CMAJ 2000;163:403-408.
ABSTRACT | FULL TEXT  

Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; B. Guidelines for Determining Whether a Drug Is Exerting (More Than) a Class Effect
McAlister et al.
JAMA 1999;282:1371-1377.
FULL TEXT  

The treatment of hypertension in Canada: Are we making progress?
McAlister
CMAJ 1999;161:713-714.
FULL TEXT  

Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease: Forecasting the Incremental Benefits of Preventing Coronary and Cerebrovascular Events
Grover et al.
Arch Intern Med 1999;159:593-600.
ABSTRACT | FULL TEXT